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Abstract
Background: Human T-lymphotropic virus type-1 (HTLV-1) causes adult T-cell leukemia/
lymphoma and is linked to a number of lymphocyte-mediated disorders. HTLV-1 contains both
regulatory and accessory genes in four pX open reading frames. pX ORF-II encodes two proteins,
p13 and p30, whose roles are still being defined in the virus life cycle and in HTLV-1 virus-host cell
interactions. Proviral clones of HTLV-1 with pX ORF-II mutations diminish the ability of the virus
to maintain viral loads in vivo. p30 expressed exogenously differentially modulates CREB and Tax-
responsive element-mediated transcription through its interaction with CREB-binding protein/
p300 and while acting as a repressor of many genes including Tax, in part by blocking tax/rex RNA
nuclear export, selectively enhances key gene pathways involved in T-cell signaling/activation.
Results: Herein, we analyzed the role of p30 in cell cycle regulation. Jurkat T-cells transduced with
a p30 expressing lentivirus vector accumulated in the G2-M phase of cell cycle. We then analyzed
key proteins involved in G2-M checkpoint activation. p30 expression in Jurkat T-cells resulted in
an increase in phosphorylation at serine 216 of nuclear cell division cycle 25C (Cdc25C), had
enhanced checkpoint kinase 1 (Chk1) serine 345 phosphorylation, reduced expression of polo-like
kinase 1 (PLK1), diminished phosphorylation of PLK1 at tyrosine 210 and reduced phosphorylation
of Cdc25C at serine 198. Finally, primary human lymphocyte derived cell lines immortalized by a
HTLV-1 proviral clone defective in p30 expression were more susceptible to camptothecin induced
apoptosis. Collectively these data are consistent with a cell survival role of p30 against genotoxic
insults to HTLV-1 infected lymphocytes.
Conclusion: Collectively, our data are the first to indicate that HTLV-1 p30 expression results in
activation of the G2-M cell cycle checkpoint, events that would promote early viral spread and T-
cell survival.
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Human T lymphotrophic virus type 1 (HTLV-1) is the eti-
ological agent of adult T cell leukemia/lymphoma (ATL),
which in its acute form is a highly aggressive CD4+ T-cell
cancer that is refractory to standard therapies (reviewed in
[1-3]). As a complex retrovirus, the HTLV-1 genome
encodes structural, enzymatic, regulatory and accessory
proteins[2,4]. The pX region of the virus contains four
open reading frames (ORFs). ORFs III and IV encode the
well characterized Rex and Tax proteins, respectively. Tax
is a 40 kDa nuclear phosphoprotein that increases viral
transcription from the HTLV-1 LTR (reviewed in [5-7]).
The ability of HTLV-1 to cause T-cell transformation is
linked to deregulation of cellular gene expression and cell
cycle checkpoints by Tax [5]. Rex is a 27 kDa nucleolar
phosphoprotein that increases the cytoplasmic accumula-
tion of non-spliced and singly spliced viral RNA (reviewed
in [8]). In contrast to the extensive knowledge about the
structure and function of Tax and Rex, less is known about
the role of pX ORF I and II-encoded proteins in the repli-
cation cycle and pathogenesis of HTLV-1.
HTLV-1 p30 is a 241 amino acid nuclear localizing pro-
tein encoded by pX ORFII [9], that contains serine and
threonine-rich regions with partial homology to the POU
family of transcription factors [10]. pX ORFs II mRNA is
present in infected cell lines and freshly isolated cells from
HTLV-1-infected subjects [11] and in ATL and HAM/TSP
patients [12]. Infected human subjects form antibodies
[13] and cytotoxic T cells [14] against recombinant pro-
teins or peptides of pX ORF II proteins, confirming the
expression of the proteins in HTLV-1 in both disease
patients and asymptomatic subjects. Freshly cultured
transformed lymphocytes from HTLV-1 patients express
both Tax and p30 [15]. Our studies were the first to dem-
onstrated that pX ORF II encoding p30 is necessary for
establishment and maintenance of HTLV-1 infection in a
rabbit model [16,17]. Emerging evidence indicates that
p30 has important roles in the viral and cellular gene
expression at both the transcriptional and the post trans-
lational level [18-27]. Two recent studies indicate that p30
interacts with Rex and co-localize in nucleolar compart-
ments [27,28]. We have demonstrated that p30 also dif-
ferentially regulates CREB responsive element and Tax
responsive element mediated transcription by interacting
with CREB binding protein p300[24,26]. Our microarray
studies indicated that p30 is actually a selective repressor
of genes including some encoding cell cycle control pro-
teins, while sparing T-cell signaling pathways [25]. Con-
sistent with these findings, a recent study indicated that
p30 has the ability to enhance Myc-associated transform-
ing activities and increase S-phase cell cycle progression
through its interactions with both Myc and the 60 kDa
Tat-interacting protein (TIP-60) [15]. Collectively these
studies support the role of p30 as a multi-functional pro-
tein with transcriptional and post-transcriptional activi-
ties that balances the influence of Tax to regulate viral
gene expression and modulates the transcriptional con-
trol of the cell cycle.
Transition through the G2/M checkpoint in mammalian
cells is strictly controlled by coordinated phosphorylation
and dephosphorylation events [29,30]. Cdc25C catalyzes
the onset of mitosis [31], but its activity is strictly regu-
lated throughout the cell cycle through differential phos-
phorylation [32]. Phosphorylation of Cdc25C at serine
216 is mediated primarily by check point kinases 1 and 2
(Chk1 and Chk2) [33], which are activated upon DNA
damage resulting in enhanced phosphorylation of
Cdc25C at serine 216 and G2 arrest [34-37]. The activity
of Cdc25C is increased during the G2-M phase of the cell
cycle by hyperphosphorylation of Cdc25C catalyzed by
both Cdc2 and PLK [38-41].
Herein, we report that expression of p30 in Jurkat T-cells
results in an accumulation of cells in the G2 phase of cell
cycle. Our data indicates that expression of HTLV-1 p30
resulted in an increase in phosphorylation of Cdc25C at
serine 216 and enhanced nuclear localization of phos-
phorylated Cdc25C at serine 216. Furthermore, the acti-
vated form of Chk1 phosphorylated at serine 345 was
increased in p30 expressing Jurkat T-cells. p30 expression
was also associated with a decrease in expression of PLK1
and diminished phosphorylation of PLK1 at tyrosine 210.
Consistent with less PLK1, p30 expression resulted in
reduced phosphorylation of Cdc25C at S-198. Finally, pri-
mary human lymphocyte derived cell lines immortalized
by an HTLV-1 proviral clone defective in p30 expression
were more susceptible to camptothecin induced apopto-
sis. Collectively, our data indicate that HTLV-1 p30
expression modulates regulatory cell cycle control in T-
cells to enhance early viral spread and prolong cell sur-
vival.
Results
Our microarray data indicated that p30 modulates a
number of genes in T-cells including genes involved in cell
cycle and apoptosis control[25]. To examine if p30 expres-
sion results in alteration of cell cycle, we infected Jurkat T-
cells with a p30 expressing lentivirus and tested the
expression of the viral protein by western blot assay (Fig.
1A). p30 mRNA levels were similar between Jurkat T-cells
expressing p30 and a primary human lymphocyte derived
cell line immortalized by an HTLV-1 full-length proviral
clone (ACH.2)[42,43] by reverse transcriptase PCR (Fig.
1B). Typically at least 88 – 92 % of Jurkat T-cells were GFP
positive in both p30 and mock Jurkat T-cells by FACS in
four trials (data not shown). We then synchronized p30
and mock transduced Jurkat T-cells at the G1/S boundary
by hydroxyl urea treatment to test their ability to progressPage 2 of 15
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collected at indicated time points and stained with pro-
pidium iodide and monitored for their progression
through the cell cycle by flow cytometry.
At 4 h after release, cells started to enter the G2/M phase
of cell cycle in both p30 expressing and mock Jurkat T-
cells. However, as compared to mock transduced cells,
p30 transduced Jurkat T-cells had a higher proportion of
cells at the G2/M phase of cell cycle, particularly between
6 to 10 h in 4 independent trails (Fig. 2A and 2B). The
observed increase in G2/M population in p30 expressing
Jurkat T-cells may be attributed to a faster S phase exit.
However, we did not see any significant difference in S
phase population between mock or p30 expressing Jurkat
T-cells (Fig. 2C). p30 expression resulted in a doubling of
the number of Jurkat T-cells in G2 phase of the cell cycle
by 6 h after release from synchronization (Fig. 2D). Thus,
p30 expression resulted in increased accumulation of cells
in the G2/M phase of cell cycle. We hypothesized that if
p30 mediated a delay in G2 exit, then the rate at which
p30 Jurkat T-cells divide should be different from mock
(lentivirus vector lacking p30) transduced Jurkat T-cells.
To examine the effect of p30 expression on cell prolifera-
tion over an extended time period (1–5 days), we com-
pared viable cell numbers of p30-expressing versus mock
infected Jurkat T-cell lines using trypan blue exclusion
assay. The number of p30-expressing Jurkat T-cells was
significantly reduced compared to mock infected Jurkat T-
cells (Fig. 2E). The slower proliferation rate of p30 trans-
duced Jurkat T-cells in these longer term proliferation
assays was consistent with the observed G2 cell cycle delay
exhibited by p30 expressing cells.
Adult T-cell leukemia/lymphoma is a highly aggressive
CD4+ T-cell malignancy that is refractory to conventional
chemotherapeutic intervention [1]. To test the influence
of p30 on the ability of T-cells immortalized by HTLV-1 to
resist drugs that induce apoptosis, we used cell lines
derived from primary human T-cells that were immortal-
ized by wild type HTLV-1 (ACH.1) and a clone of HTLV-1
that is mutated to prevent expression of p30 (ACH.30.1)
as previously described [17,42,44]. To determine if the
ACH.1 and ACH.30.1 cell lines would display differential
Expression of p30 in Jurkat T-cellsFigure 1
Expression of p30 in Jurkat T-cells. A) 40 μg of whole cell extract (Wc) prepared from mock or p30 transduced Jurkat T-
cells was loaded on a 10% SDS PAGE gel and analyzed using anti-HA antibody. B) Semi-quantitative RT-PCR: A comparison of 
p30 mRNA levels in p30 transduced Jurkat T-cells and ACH.2 cells. Graph represents relative amounts of p30 II mRNA in p30 
Jurkat T-cells and ACH.2 normalized to β-2 microglobulin.Page 3 of 15
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lowing treatment with various apoptosis inducing agents,
camptothecin, etoposide, and TRAIL. Camptothecin is a
topoisomerase I inhibitor, which induces apoptosis in
cells in the S phase of the cell cycle (reviewed in [45]).
Etoposide is a topoisomerase II inhibitor, which induces
apoptosis via the intrinsic pathway[46,47]. TRAIL is a
member of the TNF ligand family, which induces apopto-
sis through activating the death receptors (reviewed in
[48]). In independent trials, camptothecin induced apop-
tosis in the ACH.30.1 cell line to a greater degree than in
the ACH.1 cell line (nonparametric Wilcoxon rank sum
test, p-value 0.03) (Fig. 3A). Camptothecin effectively
induces apoptosis in cells in the S phase of the cell cycle.
This increased susceptibility to camptothecin-induced
apoptosis in the ACH.30.1 cell line is likely due to the
unabated influence of Tax expression driving cells into the
S phase, which would typically be counteracted by p30
[26]. These results are consistent with a recent report [15].
Following treatment with etoposide, there was no signifi-
cant difference in the degree of apoptosis induction
between ACH.1 and ACH.30.1 cell lines (nonparametric
Wilcoxon rank sum test, p-value 0.25) (Fig. 3B). Both
ACH.1 and ACH.30.1 cell lines lack TRAIL receptor
expression and were not susceptible to TRAIL-mediated
apoptosis (nonparametric Wilcoxon rank sum test, p-
value 0.59 and 0.41, respectively) (Fig. 3B). Jurkat T-cells
served as positive control for the apoptotic induction pro-
tocols and were susceptible to all treatments (Fig. 3C).
We then tested the influence of exogenously expressed
p30 on susceptibility of cells to apoptosis independent of
other viral proteins. p30 was transiently expressed in Jur-
kat T-cells and 292T cells and tested for susceptibility to
apoptotic stimuli. Expression of p30 in Jurkat T-cells did
not result in increased apoptosis when left untreated,
compared to mock infected cells, consistent with recent
findings that p30 does not induce apoptosis in transiently
transfected Molt-4 lymphocytes[15]. p30-expressing Jur-
kat T-cells and mock infected Jurkat T-cells were treated
with camptothecin, etoposide, or TRAIL and assayed for
apoptosis (Fig. 4A). Although the transduced cells were
induced into apoptosis following treatment with camp-
tothecin, etoposide, and TRAIL, there was no significant
difference in the percentage of apoptotic cells between
p30-expressing T-cells and mock Jurkat T-cells for any of
the treatment groups (nonparametric Wilcoxon rank sum
test, p values: camptothecin 0.82, etoposide 0.51, TRAIL
0.13). To examine the role of p30 in modulating cellular
apoptosis in other cell types, we transiently transfected
293T cells with either pME-p30 HA or empty vector con-
trol (pME-18S). Following treatment with camptothecin
or etoposide, cells were tested for apoptosis using immu-
noblot assay for the 89 kd fragment of cleaved PARP. Con-
sistent with our data using Jurkat T-cells, we did not
observe an increase in susceptibility to apoptosis between
p30-expressing cells and negative control cells (Fig. 4B),
and lead us to further test the influence of the viral protein
in cell cycle regulation.
To further examine p30 mediated G2 delay, we next tested
the expression of cyclin B1 and Cdc2 in p30 expressing
Jurkat T-cells. During cell cycle progression, the G2-M
transition is mediated by active Cdc2 and cyclin B1 com-
plex [49]. Our data indicated that asynchronous Jurkat T-
cells expressing p30 had no change in cyclin B1, Cdc2, or
phosphorylated Cdc 2 at tyrosine 15, but a 1.5 fold
decrease in phosphorylation of Cdc2 at threonine 161
compared to mock infected Jurkat T-cells (Fig. 5B and Fig.
6B). These results lead us to further examined proximal
signals of cell cycle regulation that could explain a delay
in G2/M transition in p30 expressing T-cells.
The activity of Cdc2 is regulated by the phosphatase
Cdc25C. Dephosphorylation of Cdc2 at threonine 14 and
tyrosine 15 by Cdc25C results in activation of Cdc2 and
initiation of an autoactivation loop between Cdc25C and
Cdc2 that efficiently drives cells into mitosis. We reasoned
that since p30 expression is associated with a decrease in
phosphorylation of Cdc2 at threonine161, we anticipated
a less active form of Cdc25C. To test this hypothesis we
examined the expression and phosphorylation status of
Cdc25C in p30 and mock Jurkat T-cells. No change was
observed in the amounts of nuclear Cdc25C in p30
expressing Jurkat T-cells (Fig. 5C) or transcript levels of
Cdc25C by reverse transcriptase PCR when compared to
mock transduced Jurkat T-cells (data not shown).
We next tested the phosphorylation status of Cdc25C at
serine 216 using phosphospecific antibodies by western
blot assay. Interestingly, p30 expression resulted in
enhanced phosphorylation of Cdc25C at serine 216 and
an increase in accumulation of the phosphorylated form
in the nucleus in both p30 transduced Jurkat T-cells (Fig.
5C) and 293T cells transfected with pME p30 (data not
shown). These data indicate that p30 expression was asso-
ciated with an increase in nuclear accumulation of
Cdc25C phosphorylated at serine 216, consistent with a
delay in G2 exit from the cell cycle.
Phosphorylation of Cdc25C at serine 216 is mediated pri-
marily by Chk1 and other kinases including Chk2 or
Cdc25C associated kinase (cTAK1). Chk1 is activated by
phosphorylation mediated by ataxia telangiectasia
mutated and rad 3 related kinase (ATR) in response to sin-
gle stranded DNA breaks[50]. We therefore examined the
phosphophorylation status of Chk1 at serine 345 in p30
expressing and mock infected Jurkat T-cells. Consistent
with enhanced phosphorylation of Cdc25C at serine 216
and a delay in G2 exit from the cell cycle, we observed anPage 4 of 15
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Progression of p30 expressing Jurkat T-cells through G2-M is delayedFigu  2
Progression of p30 expressing Jurkat T-cells through G2-M is delayed. A) Cell cycle distribution of mock or p30 
transduced Jurkat T-cells at 6 h post release from hydroxyl urea block by propidium iodide staining followed by FACS analysis. 
Histogram was generated using ModFitRprogram (Verity Software House, Topsham, ME). Data represented is from one of the 
4 independent trials B) A comparison of percentage of cells in the G2-M phase of the cell cycle of p30 and mock transduced 
Jurkat T-cells at indicated time points post hydroxyl urea release. Data represented is from a different trial than A. C) A com-
parison of percentage of cells in the S phase of cell cycle of p30 and mock transduced Jurkat T-cells at indicated time points 
post hydroxyl urea release. Data represented is from the same trial as B. D) Fold increase of cells in G2 phase of cell cycle in 
p30 Jurkat T-cells of 4 independent experiments was calculated by dividing the number of cells in G2 phase of cell cycle in p30 
Jurkat T-cells over mock Jurkat T-cells. E) p30-expressing Jurkat T-cells or mock infected Jurkat T-cells were assayed for 
growth using a trypan blue exclusion assay. The p30-expressing Jurkat T-cell line growth curve differed from that of the mock 
infected Jurkat T-cell line (p-value 0.02 after adjusting for time in a quadratic model) due to an initial lag in the p30-expressing 
Jurkat T-cell growth rate compared to that of the mock infected Jurkat T-cells. By day 5, p30- expressing Jurkat T cell cultures 
had fewer total cell numbers compared to mock infected Jurkat T cell cultures (nonparametric Wilcoxon rank sum test, p-
value 0.05). Bars indicate 95 % confidence interval.
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Differential camptothecin-induced apoptosis in HTLV-1 immortalized cell linesFigu  3
Differential camptothecin-induced apoptosis in HTLV-1 immortalized cell lines. A) ACH.1 and ACH.30.1 cell lines 
were exposed to various apoptosis inducing agents and assayed for percentage of cells induced into apoptosis via Annexin V 
flow cytometry. Data represents the results of at least three independent experiments. Jurkat T-cells were used as a positive 
control. Representative result of Annexin V flow cytometry following apoptosis induction with camptothecin. Apoptotic frac-
tion is seen in the lower right quadrant by FACS analysis. B) Following treatment with camptothecin, a greater percentage of 
ACH.30.1 cells were induced into apoptosis compared to ACH.1 cells (nonparametric Wilcoxon rank sum test, p-value 0.03). 
ACH.30.1 cells and ACH.1 cells were induced into apoptosis to an equal degree following treatment with etoposide (nonpara-
metric Wilcoxon rank sum test, p-value 0.25). Neither ACH.1 nor ACH.30.1 cells were induced into apoptosis following treat-
ment with TRAIL (nonparametric Wilcoxon rank sum test, p-value 0.59 and 0.41, respectively). C) As a positive control, 
apoptosis was induced in Jurkat T-cells with all apoptosis inducing agents. * Statistically significant apoptosis induction; ** Statis-
tically more apoptosis induction in ACH.30.1 cells compared to ACH.1 cells following treatment with camptothecin. Standard 
error bars are indicated.
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HTLV-1 p30 does not modulate apoptosis in 293T cells or Jurkat T-cellsFigure 4
HTLV-1 p30 does not modulate apoptosis in 293T cells or Jurkat T-cells. A) p30-expressing Jurkat T-cells or mock 
infected Jurkat T-cells were treated with camptothecin, etoposide, or TRAIL and assayed for apoptosis induction via Annexin V 
flow cytometry. Data represents the results of three independent experiments. Although camptothecin, etoposide, and TRAIL 
induced both cell lines into apoptosis, a differential degree of apoptosis induction was not seen between the two cell lines 
(nonparametric Wilcoxon rank sum test, p values: camptothecin 0.82, etoposide 0.51, TRAIL 0.13). Standard error bars are 
indicated. B) 293T cells were transiently transfected with either pME-p30HA or the empty pME-18S vector. Cells were 
untreated or treated with camptothecin or etoposide. Cell lysates were harvested and 50 μg of lysate was separated by SDS-
PAGE. Apoptosis was assayed via immunoblot for the 89 kDa fragment of cleaved PARP. Expression of p30 was verified via 
immunoblot for HA. Expression of β-actin was verified as a loading control. - cells transfected with empty vector control; + 
cells transfected with pME-p30HA.
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p30 enhances phosphorylation of Cdc25C at S-216Figure 5
p30 enhances phosphorylation of Cdc25C at S-216. A) 40 ug of nuclear (N) or cytosolic (C) fraction prepared from 
either p30 expressing or Mock Jurkat T-cells were loaded on 10% SDS gel and western blot analysis was performed with anti-
HA to confirm p30 expression and Histone H1 western to confirm nuclear and cytosolic fractionation. B) Western blot of 
nuclear (N) and cytosolic (C) extracts prepared from p30 or mock Jurkat T-cells probed with anti-Cdc2 and phosphospecific 
Cdc2 antibody. C) Western blot of nuclear (N) and cytosolic (C) extracts prepared from p30 or mock Jurkat T-cells, probed 
with anti-Cdc25C or phosphospecific anti-Cdc25C. D) Western Blot analysis of nuclear or cytosolic extracts from p30 or 
mock Jurkat T-cells, probed with anti-Chk1 or monoclonal phosphospecific Chk1 (S-345).
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PLK1 protein level is reduced in p30 Jurkat T-cells and overall quantified comparisonsFigure 6
PLK1 protein level is reduced in p30 Jurkat T-cells and overall quantified comparisons. A) Western blot analysis of 
cytosolic (C) or nuclear extract (N) prepared from either p30 expressing or mock Jurkat T-cells and probed with anti-PLK1, 
pPLK-1(T-210) and pCdc25C(S-198). β-actin was used as a loading control. B) Densitometric analysis of western blot: Band 
intensity was quantified by Gel-Pro Analyzer 3.1® and normalized to β-actin. Graph represents densitometric analysis of 4 inde-
pendent western blots for each of the represented proteins.
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and 6B).
Phosphorylation of Cdc25C at serine 198 by PLK1 results
in nuclear localization of Cdc25C by eliciting a conforma-
tional change that conceals its nuclear export signal
[40,41] and therefore PLK-1 has been described as a posi-
tive regulator of G2/M transition [51]. Polo-like kinase 1
also phosphorylates cyclin B1 and promotes nuclear accu-
mulation of the cyclin B1-Cdc2 hetero dimmer [52]. Polo-
like kinase 1 is activated upon phosphorylation at threo-
nine 210 and serine 137 and phosphorylation at these
sites is inhibited upon DNA damage to prevent cells from
entering mitosis [53]. We therefore examined if PLK1 pro-
tein levels were altered in p30 expressing versus mock Jur-
kat T-cells. Interestingly, p30 expression resulted in
reduced amounts of detectable PLK1 and the threonine
210 phosphorylated form of PLK-1 (Fig. 6A). Finally, we
examined the phosphorylation status of Cdc25C at serine
198. Consistent with less PLK1, p30 expression resulted in
reduced phosphorylation of Cdc25C at serine 198 (Fig.
6A). These data further supported our observed G2/M
delay as PLK1 promotes G2/M transition. Using PLK1 spe-
cific primers, we examined the transcript levels of PLK1 in
p30 and mock transduced Jurkat T-cells by reverse tran-
scriptase PCR and found that p30 did not result in
decrease in PLK1 transcript levels (data not shown). The
fold change in expression of key G2/M cell cycle regula-
tory proteins in p30 expressing Jurkat T-cells is summa-
rized in Fig. 6B.
Discussion
The ability of HTLV-1 to promote T-cell survival is critical
to allow the virus to spread cell-to-cell following infection
prior to an active immune response. This permits the virus
to establish an infection that is maintained life-long
through regulated virus expression and clonal expansion
of infected lymphocytes [54]. Multiple studies indicate
the importance of HTLV-1 ORF II expression during the
course of the natural infection. Infected human subjects
exhibit antibody and cytotoxic T cell responses against
recombinant proteins or peptides of pX ORF II pro-
teins[13,14] and freshly cultured transformed lym-
phocytes from HTLV-1 patients express both Tax and p30
[15]. We were the first to demonstrated that pX ORF II
encoding p30 is necessary for establishment and mainte-
nance of HTLV-1 infection in a rabbit model [16,17]. In
this study, we sought to determine if p30 has a functional
role in modulating T-cell survival. Herein, we report that
expression of p30 in Jurkat T-cells results in an accumula-
tion of cells in the G2 phase of cell cycle. Expression of the
viral protein resulted in an increase in phosphorylation of
Cdc25C at serine 216, which was presented in greater
amounts in the nucleus of p30 expressing cells. The acti-
vated form of Chk1 phosphorylated at serine 345 was
increased in p30 expressing Jurkat T-cells concurrent with
a decrease in expression of PLK1 and the phospho-tyro-
sine 210 form of PLK1. Consistent with less PLK1, p30
expression resulted in reduced phosphorylation of
Cdc25C at S-198. Interestingly, primary human lym-
phocyte derived cell lines immortalized by an HTLV-1
proviral clone defective in p30 expression were more sus-
ceptible to camptothecin induced apoptosis. Collectively,
our data indicate that HTLV-1 p30 expression modulates
regulatory cell cycle control in T-cells resulting in accumu-
lation of cells in G2-M phase of cell cycle, which would
enhance early viral spread and prolong lymphocyte sur-
vival.
The effects of p30 in modulation of the cell cycle contrast
to the influence of HTLV-1 Tax on cell cycle regulation. We
have recently demonstrated that p30 balances and coun-
teracts the influence of Tax [26]. Tax has been reported to
interact directly with Chk-2 resulting in attenuation of
DNA damage induced signaling in an ATM/chk2-medi-
ated pathway dependent manner [55]. Our data indicates
that p30 results in G2-M delay by enhancing Chk-1 phos-
phorylation. In response to DNA damage, ATR kinase
phosphorylates and activates Chk1 resulting in G2 arrest
[50]. Thus, p30 may be involved in a DNA damage/repair
signaling pattern, similar to HIV-1 Vpr [56-58]. Our cur-
rent studies indicate that p30 enhances DNA damage/
repair signaling in an ATM dependent manner (manu-
script in preparation) and suggest a role in integration
allowing DNA repair to take place. Thus, p30 counteracts
some of the cellular effects of Tax, which if not regulated,
could cause premature cell death by apoptosis or a more
rapid oncogenic transformation event, which would be
detrimental for long-term viral persistence.
HTLV-1 is the etiologic agent of adult T-cell leukemia/
lymphoma a highly aggressive CD4+ T-cell malignancy
affecting approximately 1–5 % of HTLV-1-infected indi-
viduals after a latent period as long as three decades [1].
Our data has implications in our understanding of how
the virus establishes infection and immortalizes T-cells in
a manner that results in a relative resistance to drug
induced apoptosis. T-cells immortalized with HTLV-1
proviruses lacking p30 expression (ACH.30.1) were more
susceptible to camptothecin-induced apoptosis. Camp-
tothecin is a topoisomerase I inhibitor, which induces
apoptosis in cells in the S phase of the cell cycle (reviewed
in [45]). We have recently demonstrated that p30 bal-
ances and counteracts the influence of Tax [26]. Without
the dampening influence of p30 on Tax, the ACH.30.1
cells would be predicted to be more in the S phase of the
cell cycle and susceptible to drugs such as camptothecin.
Thus, p30 effects upon the cell cycle, in particular during
the early phase of viral spread in vivo may enhance cell
survival and promote cell to cell spread of the infection.Page 10 of 15
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of expression of a variety of cellular genes, including many
cell cycle and apoptosis regulatory genes [15,25]. To fur-
ther test potential mechanisms for our observed p30
mediated G2 delay, we tested the expression status of cyc-
lin B1 and Cdc2 key mediators of the G2-M transition. We
did not see a change in cyclin B1 or Cdc2 in either p30
expressing or mock Jurkat T-cells. However, p30 expres-
sion was associated with a decrease in phosphorylation at
threonine 161 supporting the G2 delay observed in p30
expressing Jurkat T-cells. Cdc2 is activated by Cdc25C that
removes phosphate groups from tyrosine 15 and threo-
nine 14 [31]. Activated Cdc2 can further activate Cdc25C
[39]. We therefore looked at the expression and phospho-
rylation status of Cdc25C by western blot analysis. When
phosphorylated at serine 216, Cdc25C is typically shut-
tled out of the nucleus by the cytoplasmic anchor protein
complex 14-3-3 and therefore excluded from its substrate
[32]. We found that p30 expression resulted in reduced
protein levels of Cdc25C. It is possible that p30 may
repress Cdc25C expression at the transcriptional or post-
transcriptional level. We also observed that p30 expres-
sion was associated with enhanced phosphorylation of
Cdc25C at serine 216. Interestingly we found an increase
in nuclear accumulation of Cdc25C phosphorylated at
serine 216, which primarily is localized in the cytoplasm.
It is possible that p30 might interfere with nuclear export
of the protein and therefore cause an accumulation
pCdc25C serine 216 in the nucleus. It is also possible that
p30 might result in decreased 14-3-3 expression or
directly bind with 14-3-3 and result in lesser amounts of
14-3-3 available for binding to and shuttling of pCdc25C
serine 216. Our data indicates that p30 expression results
in increased amounts of cellular Chk1 serine 345 phos-
phorylated forms to accumulate, consistent with the
increased phosphorylation of Cdc25C.
Polo-like kinase 1 phosphorylates Cdc25C at serine 198
and allows the nuclear retention of Cdc25C by concealing
the nuclear export signal [41]. ATR kinase inactivates
PLK1 in response to DNA damage. Our data indicates that
p30 expression was associated with decreased PLK1 and
its threonine 210 phosphorylated form. Reduced total lev-
els of PLK-1 may be because p30 may modulate PLK-1
expression at the transcriptional or posttranscriptional
level or may affect stability of PLK-1 protein. Future stud-
ies are directed towards understanding the role of p30 in
PLK-1 expression.
Consistent with the less active form of PLK-1, reduced
phosphorylation of Cdc25C at serine 198 was associated
with p30 expression. We expected that if PLK1 expression
is low, we should see more cytosolic form of Cdc25C.
However in our studies we find that Cdc25C phosphor-
ylated at serine 216 is increased in the nucleus. These data
suggests that p30 may inhibit the nuclear export of
Cdc25C similar to its effects on tax/rex mRNA [8,21].
Our data suggests parallels between the function of HTLV-
1 p30 and HIV-1 Vpr, which is associated with G2 arrest
[56]. The biological significance of this arrest during the
natural infection is not well understood but the HIV-1
LTR seems to be more active in the G2 phase, suggesting
that G2 arrest confers a favorable cellular environment for
efficient transcription of HIV-1 [59]. Vpr induced cell
cycle arrest requires ATR kinase for the activation of Chk1
that results in phosphorylation and inactivation of
Cdc25C [60]. In this regard it will be important to test
HTLV-1 LTR activity during the G2 phase of cell cycle and
the viral proteins effect upon proviral integration. HIV-1
Vpr expression may increase Survivin expression during
G2/M to regulate cell viability during HIV-1 infection
[61]. Similarly, p30 may serve to prolong the survival of
HTLV-1 infected cells by up regulating key cellular gene
products like Survivin to prevent apoptosis and elimina-
tion of HTLV-1 infected cells.
Conclusion
Overall, our data indicates a role for p30 in modulating
cell cycle parameters of T-cells providing new insights
how HTLV-1 regulates its cellular environment and bal-
ances the effects of Tax, which if unchecked would result
in rapid immune elimination of virus producing host cells
or cause cell death by apoptosis, both detrimental for viral
persistence, a hallmark of the natural infection.
Methods
Cell lines
ACH.1 and ACH.30.1 cell lines were obtained from out-
growth of immortalized PBMCs transfected with the ACH
or ACH.p30 II clones, respectively[42,44]. Cells were
maintained in RPMI 1640 supplemented with 15 % fetal
bovine serum, L-glutamine (30 ug/ml), penicillin (100
μg/mL), streptomycin (100 μg/mL), and recombinant IL-
2 (10 U/mL) (complete medium). The 293 cell line is a
human embryonic kidney epithelial cell line (catalog
number 1573, American Type Culture Collection, Manas-
sas, VA). 293T is a clone of the 293 cell line which stably
expresses the simian virus 40 (SV40) T antigen (G. Franch-
ini, National Cancer Institute). 293T cells were main-
tained in modified Dulbecco's Eagle medium containing
10 % fetal bovine serum and streptomycin (100 ug/mL)
and penicillin. Jurkat T-cells (American Type Culture Col-
lection clone E6-1; catalognumberTIB-152) were main-
tained in RPMI 1640 supplemented with 15 % fetal
bovine serum, penicillin (100 μg/mL), streptomycin (100
μg/mL), and L-glutamine (30 ug/mL).Page 11 of 15
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cells
Generation of the pWPT-p30HA-IRES-GFP and pWPT-
IRES-GFP lentiviral vectors has been described[25]. The
pME-p30HA and pME-18S plasmids have also been
described[25]. Production of recombinant lentivirus and
transduction of Jurkat T-cells with pWPT-IRES-GFP and
pWPT-p30HA-IRES-GFP has been described[25]. Cells
were analyzed for p30 expression by western immunob-
lotting and GFP expression by flow cytometric analysis
(FACS).
Cell cycle analysis
p30 or GFP transduced Jurkat T-cells were synchronized
with 2 mM hydroxyl urea (Sigma) for 14 h followed by
release for 6 h and a second hydroxy urea block for 16 h.
Synchronized cells were released from the block and col-
lected at 0, 2, 4, 6, 8, 10, 12, 24 h. Cells were fixed in 70
% ethanol at kept at 4°C for 14 h. Cells were then washed
with PBS and treated with DNAse free RNAse (Roche,
Indianapolis, IN) for 30 min in PBS containing 0.1 % tri-
ton X-100 at 37°C followed by staining with propidium
iodide (Sigma) and analyzed by BD FACS Calibur system
® (BD Biosciences, San Jose, CA).
Assays to test susceptibility to apoptotic agents
For lymphocyte cell lines (ACH.1, ACH.30.1, Jurkat T
cells), apoptosis was induced with camptothecin (10 μM,
4 h)[62], etoposide (12 μg/mL, 6 h)[63], and TRAIL (TNF-
related apoptosis inducing ligand) (1 μg/mL, 2 h) [64].
293T cells were induced into apoptosis with camp-
tothecin (10 μM, 24 h)[65] and etoposide (12 μg/mL, 24
h) [66]. Drug doses were optimized for maximal apopto-
sis induction prior to each experiment.
Flow cytometry
ACH.1, ACH.30.1, and Jurkat T cells were prepared for
flow cytometry by labeling with Annexin V Alexa Fluor®
488 conjugage (Molecular Probes, Eugene, OR) and pro-
pidium iodide (PI) (Molecular Probes) or Annexin V Alex-
aFluor® 647 conjugate (Molecular Probes) according to
the manufacturer's protocol. In brief, the cells were col-
lected, washed once with PBS, and re-suspended at 1 × 106
cells/mL in 100 μL of Annexin-binding buffer (Molecular
Probes), followed by incubation with 5 μL Annexin V con-
jugate solution and 1 μL 100 μg/mL PI for 15 min at room
temp. After the incubation period, 400 μL of Annexin-
binding buffer was added, and samples were kept on ice.
The samples were analyzed by flow cytometry (Coulter
Epics Elite, Beckman Coulter Inc., Fullerton, CA) and data
were analyzed using Coulter Flow Center software (Beck-
man Coulter Inc.). For each sample, 10,000 gated cells
were examined for Annexin V and PI staining, and the per-
centage of cells in early apoptosis was defined by high
Annexin V- and low PI-staining cell population. All
Annexin V assays were performed in a minimum of three
independent experiments. Nonparametric Wilcoxon rank
sum test was used for statistical analysis of significant
apoptosis induction and comparison of apoptosis induc-
tion between cell lines.
Transient transfections
Subconfluent 293T cells were transfected with 15 μg of
either pME-p30 HA or pME-18s using Superfect ® (Qiagen,
Valencia, CA) according to manufacturer's protocol. After
48 h, transfected cells were washed with PBS and lysed
with RIPA buffer (150 mM NaCl, 0.01 M sodium pyro-
phosphate, 10 mM EDTA, 10 mM sodium fluoride, 50
mM Tris (pH 8.0), 0.1% SDS, 12.8 mM deoxycholic acid,
10 % glycerol, 1 % NP-40) containing one complete mini
protease inhibitor cocktail tablet (Roche Applied Science,
Indianapolis, IN). Cell suspensions were incubated on ice
for 20 min and the lysates were centrifuged at 14,000 rpm
for 20 min at 4°C. Supernatant was stored at -80°C.
Western blot assays
Expression of cell cycle regulators were analyzed using
nuclear and cytosolic extracts. Briefly, cells were swelled in
hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2,
10 mM KCl) followed by shearing with a 27 gauge needle
followed by centrifugation at 14000 rpm for 15 sec.
Supernatant were saved as cytosolic fractions and nuclear
pellets were incubated with high salt buffer for 1 h (20
mM HEPES pH 7.9, 25 % glycerol, 1.5 mM MgCl2, 1.2 M
KCl, 0.2 mM EDTA) followed by low salt buffer (20 mM
HEPES pH 7.9, 25 % glycerol, 1.5 M MgCl2, 0.02 M KCl,
0.2 mM EDTA) and centrifuged at 14000 rpm for 30 min
to get nuclear extract. Membranes were blocked with 5 %
non-fat dry milk and 10 % fetal bovine serum in Tris-buff-
ered saline with 0.1 % Tween (TBST) for 2 h at room
temp., then incubated with primary antibody overnight at
4°C. Immunodetection was performed using the follow-
ing antibodies: mouse anti-HA monoclonal antibody
clone 16B-12 (1:1000, Covance Research Products, Princ-
eton, NJ), mouse monoclonal anti-PARP clone C-2-10
(1:1000, Oncogene Research Products, Boston, MA).
mouse monoclonal anti-β-actin clone AC-74 (1:4000,
Sigma), rabbit polyclonal anti-Cdc2 # 9112 (1:1000, Cell
Signaling, Beverly, MA), rabbit polyclonal anti-
PLK1pT210 # 600-401-466 (1: 1000, Rockland, Gilberts-
ville, PA), polyclonal rabbit anti-Cdc2 T-161 #9114
(1:1000, Cell Signaling), polyclonal rabbit anti Cdc2 Y-15
#9111(1:1000, Cell Signaling), polyclonal rabbit anti-
Cdc25C #9522 (1:1000, Cell Signaling), polyclonal rabbit
anti-Cdc25C S-216 # 9528(1:1000, Cell Signaling), rabbit
polyclonal anti-Cdc25C pS-198 # 9529 (1: 1000, Cell Sig-
naling), polyclonal rabbit anti-Chk1 #2345 (1:1000, Cell
Signaling), polyclonal rabbit anti-Chk1 S-345 #2341 (1:
1000, Cell Signaling), rabbit polyclonal anti-PLK1 (1:
1000) (Abcam, Cambridge, MA), mouse monoclonalPage 12 of 15
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blots were developed with horseradish peroxidase-labeled
secondary antibody (1:1000) and enhanced chemilumi-
nescence reagent (Cell Signaling Technology). All western
blots were repeated at least four times.
Reverse transcriptase PCR
RNA was isolated from p30 Jurkat T-cells and ACH.2 cells
using RNAqueous™(Ambion, Auatin, TX)). Two step RT-
PCR was performed by using random primers to prepare
cDNA followed by PCR using specific primers for indi-
cated genes. p30 primers were used as described[25]. For
β-2 microglobulin the following primer set (Invitrogen)
was used F5-ACCCCCACTGAAAAAGATAC-3 and R5-
ATCTTCAAACCTCCATGATG-3. Cycles were varied from
15 cycles to 30 cycles in order to compare transcript levels
between p30 Jurkat T-cells and ACH.2 cells. β-2
microglobulin was used as a control to compare expres-
sion levels. PCR products were run on an agarose gel and
stained with ethidium bromide and p30 band was quan-
tified and normalized to β-2 microglobulin band using
Alphamager® 3.24.
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